Navigation Links
Celator(R) Pharmaceuticals To Present at 2008 BIO Investor Forum
Date:10/23/2008

PRINCETON, N.J., Oct. 23 /PRNewswire/ -- Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, is scheduled to present at the BIO Investor Forum in San Francisco. Mr. Jackson will provide a corporate overview and an update on the company's clinical development programs. The presentation will be held on Wednesday, October 29, 2008 at 1:45 PM PDT in the Marina Room of the Palace Hotel.

The company is also pleased to announce that Dr. Arthur Louie, chief medical officer, has been invited to participate in a therapeutic workshop titled, "Pre-ASH Primer: Hematology Heavy Hitters Discuss What's on the Horizon." The workshop will be held on Thursday, October 30, 2008 at 9:30 AM PDT in the Twin Peak South Room of the Palace Hotel.

About Celator

Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex(R), the company's drug ratio technology platform, represents a revolutionary new approach to the development of combination therapies based on identifying a fixed, synergistic ratio of the drugs pre-clinically, incorporating that ratio in a drug delivery vehicle and maintaining the ratio in patients. The company pipeline includes: CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in a Phase 2 trial in patients with colorectal cancer; CPX-351 (a liposomal formulation of cytarabine:daunorubicin), currently in a Phase 1 trial in patients with advanced leukemia; CPX-571 (a liposomal formulation of irinotecan:cisplatin), a preclinical stage compound; and multiple research programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at http://www.celatorpharma.com.


'/>"/>
SOURCE Celator Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Celator(R) Pharmaceuticals to Present at 2008 BIO International Convention
2. Celator(R) Pharmaceuticals Announces Appointment of Scott Jackson as CEO
3. Celator(R) Pharmaceuticals to Present at 10th Annual BIO CEO and Investor Conference
4. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
5. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
6. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
7. Arena Pharmaceuticals to Report Third Quarter 2008 Financial Results and to Host Conference Call and Webcast on Thursday, October 30, 2008
8. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIOCOM Investor Conference
10. Amylin Pharmaceuticals Reports Third Quarter Financial Results
11. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 2017   Sienna Biopharmaceuticals, Inc. , a privately ... that Richard Peterson will join the company ... Peterson, who brings more than two decades of global ... is retiring at the end of April but will ... joins Sienna from Novan, Inc., where he served as ...
(Date:3/23/2017)... BETHESDA, Md. , March 23, 2017 /PRNewswire/ ... company developing DCVax® personalized immune therapies for solid ... on the $7.5 million financing it announced last ... Company sold to several institutional investors securities totaling ... $.26 per share, and 10,000,000 shares of Class ...
(Date:3/23/2017)... 2017 Kineta, Inc., a biotechnology company ... in immuno-oncology, today announced the discovery and characterization ... that activate interferon response factor 3 (IRF3) via ... tumor regression in a murine colon carcinoma mouse ... complete tumor regression to initial drug treatment were ...
(Date:3/23/2017)... ... March 23, 2017 , ... Advanced ... the hire of Dr. Sigmund “Sig” Floyd as Vice President ? Global Business ... joint development activities. , “Dr. Floyd’s career has spanned 30 years in the ...
Breaking Biology Technology:
(Date:3/22/2017)... VILNIUS, Lithuania , March 21, 2017 /PRNewswire/ ... identification and object recognition technologies, today announced the ... development kit (SDK), which provides improved facial recognition ... safety cameras on a single computer. The new ... algorithms to improve accuracy, and it utilizes a ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel visited the ... the DERMALOG stand together with the Japanese Prime Minster Shinzo Abe. ... largest German biometrics company the two government leaders could see the three ... as DERMALOG´s multi-biometrics system.   Continue Reading ... ...
(Date:3/13/2017)... 13, 2017 Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other ... identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric Face Matching on the ...
Breaking Biology News(10 mins):